The "albumin effect" and in vitro-in vivo extrapolation: Sequestration of long-chain unsaturated fatty acids enhances phenytoin hydroxylation by human liver microsomal and recombinant cytochrome P450 2C9

Drug Metabolism and Disposition

Volumn 36, Issue 5, 2008, Pages 870-877

  Rowland, Andrew ^a   Elliot, David J ^a   Knights, Kathleen M ^a   Mackenzie, Peter I ^a   Miners, John O ^a,b  

^a FLINDERS UNIVERSITY   (Australia)

^b FLINDERS MEDICAL CENTRE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ARACHIDONIC ACID; BOVINE SERUM ALBUMIN; CYTOCHROME P450 2C9; HEPTADECANOIC ACID; LINOLEIC ACID; OLEIC ACID; PHENYTOIN;

ARTICLE; BACTERIAL MEMBRANE; ENZYME INHIBITION; ESCHERICHIA COLI; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; KINETICS; LIVER MICROSOME; MASS SPECTROMETRY; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION;

ANTICONVULSANTS; ARYL HYDROCARBON HYDROXYLASES; CELL MEMBRANE; ESCHERICHIA COLI; FATTY ACIDS, UNSATURATED; HUMANS; HYDROXYLATION; MICROSOMES, LIVER; PHENYTOIN; RECOMBINANT PROTEINS; SERUM ALBUMIN;

BOVINAE; ESCHERICHIA COLI;

EID: 42449124602     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.107.019885     Document Type: Article

References (40)

1. Boase S and Miners JO (2002) In vitro-in vivo correlations for drugs eliminated by glucuronidation: investigation with the model substrate zidovudine. Br J Clin Pharmacol 54:493-503.
2. Bowalgaha K, Elliot DJ, Mackenzie PI, Knights KM, Swedmark S, and Miners JO (2005) Naproxen and desmethylnaproxen glucuronidation by human liver microsomes and recombinant human UDP-glucuronosyltransferases (UGT): Role of UGT2B7 in the elimination of naproxen. Br J Clin Pharmacol, 60:423-433.
3. Boye SL, Kerdpin O, Elliot DJ, Miners JO, Kelly L, McKinnon RA, Bhasker CR, Yoovathaworn K, and Birkett DJ (2004) Optimizing bacterial expression of catalytically active human cytochromes P450: comparison of CYP2C8 and CYP2C9. Xenobiotica 34:49-60.
4. Brown HS, Griffin M, and Houston JB (2007) Evaluation of cryopreserved human hepatocytes as an alternative in vitro system to microsomes for prediction of metabolic clearance. Drug Metab Dispos 35:293-301.
5. Carlile DJ, Hakooz N, Bayliss MK, and Houston JB (1999) Microsomal prediction of in vivo clearance of CYP2C9 substrates in humans. Br J Clin Pharmacol 47:625-635.
6. Daikh BE, Lasker JM, Raucy JL, and Koop DR (1994) Regio- and stereoselective epoxidation of arachidonic acid by human cytochromes P450 2C8 and 2C9. J Pharmacol Exp Ther 271:1427-1433.
7. Dickinson RG, Hooper WD, Patterson M, Eadie MJ, and Maguire B (1985) Extent of urinary excretion of p-hydroxyphenytoin in healthy subjects given phenytoin. Ther Drug Monit 7:283-289.
8. Doherty MM, Poon K, Tsang C, and Pang KS (2006) Transport is not rate-limiting in morphine glucuronidation in the single-pass perfused rat liver preparation. J Pharmacol Exp Ther 317:890-900.
9. Draper AJ and Hammock BD (2000) Identification of CYP2C9 as a human liver microsomal linoleic acid epoxygenase. Arch Biochem Biophys 376:199-205.
10. Folch J, Lees M, and Stanley GHS (1956) A simple method for the isolation and purification of total lipids from animal tissue. J Biol Chem 226:497-509.
11. Gugler R, Manion CV, and Azarnoff DL (1976) Phenytoin: pharmacokinetics and bioavailability. Clin Pharmacol Ther 19:135-142.
12. Hakooz N, Ito K, Rawden H, Gill H, Lemmers L, Boobis AR, Edwards RJ, Carlile DJ, Lake BJ, and Houston JB (2006) Determination of a human hepatic microsomal scaling factor for predicting in vivo drug clearance. Pharmacol Res 23:533-539.
13. Halifax D and Houston JB (2006) Uptake and intracellular binding of lipophilic amine drugs by isolated rat hepatocytes and implications for prediction of in vivo metabolic clearance. Drug Metab Dispos 34:1829-1836.
14. Houston JB (1994) Utility of in vitro drug metabolism data in predicting in vivo metabolic clearance. Biochem Pharmacol 47:1469-1479.
15. Ito K and Houston JB (2005) Prediction of human drug clearance from in vitro and preclinical data using physiologically based and empirical approaches. Pharmacol Res 22:103-112.
16. Iwatsubo T, Hirota N, Ooie T, Suzuki H, Shimada N, Chiba K, Ishizaki T, Green CE, Tyson CA, and Sugiyama Y (1997) Prediction of in vivo drug metabolism in the human liver from in vitro metabolism data. Pharmacol Ther 73:147-171.
17. Kerwin JL and Torvik JJ (1996) Identification of monohydroxy fatty acids by electrospray mass spectrometry and tandem mass spectrometry. Anal Biochem 237:56-64.
18. Kurata D and Wilkinson GR (1974) Erythrocyte uptake and plasma binding of diphenylhydantoin. Clin Pharmacol Ther 16:355-362.
19. Ludden LK, Ludden TM, Collins JM, Pentikis HS, and Strong JM (1997) Effect of albumin on estimations, in vitro, of phenytoin Vmax and Km values: implications for clinical correlation. J Pharmacol Exp Ther 282:391-396.
20. McGinnity DF, Soars MG, Urbanowicz RA, and Riley RJ (2004) Evaluation of fresh and cryopreserved hepatocytes as in vitro drug metabolism tools for the prediction of metabolic clearance. Drug Metab Dispos 32:1247-1253.
21. McLure JA, Miners JO, and Birkett DJ (2000) Non-specific binding of drugs to human liver microsomes. Br J Clin Pharmacol 49:453-461.
22. Miners JO, Smith KJ, Robson RA, McManus ME, Veronese ME, and Birkett DJ (1988) Tolbutamide hydroxylation by human liver microsomes: kinetic characterisation and relationship to other cytochrome P-450 dependent xenobiotic oxidations. Biochem Pharmacol 37:1137-1144.
23. Miners JO and Birkett DJ (1998) Cytochrome P4502C9: an enzyme of major importance in human drug metabolism. Br J Clin Pharmacol 45:525-538.
24. Miners JO, Knights KM, Houston JB, and Mackenzie PI (2006) In vitro-in vivo correlation for drugs and other compounds eliminated by glucuronidation in humans: pitfalls and promises. Biochem Pharmacol 71:1531-1539.
25. Obach RS, Baxter JG, Liston TE, Silber BM, Jones BC, MacIntye F, Rance DJ, and Wastall P (1997) The prediction of human pharmacokinetic parameters from preclinical and in vitro metabolism data. J Pharmacol Exp Ther 283:46-58.
26. Proctor NJ, Tucker GT, and Rostami-Hodjegan A (2004) Predicting drug clearance from recombinantly expressed CYPs: intersystem extrapolation factors. Xenobiotica 34:151-178.
27. Rifkind AB, Lee C, Chang TK, and Waxman DJ (1995) Arachidonic acid metabolism by human cytochrome P450s 2C8, 2C9, 2E1, and 1A2: regioselective oxygenation and evidence for a role for CYP2C enzymes in arachidonic acid epoxygenation in human liver microsomes. Arch Biochem Biophys 320:380-389.
28. Riley RJ, McGinnity DF, and Austin RP (2005) A unified model for predicting human hepatic, metabolic clearance from in vitro intrinsic clearance data in hepatocytes and microsomes. Drug Metab Dispos 33:1304-1311.
29. Rostami-Hodjegan A and Tucker GT 2007 (2007) Simulation and prediction of in vivo drug metabolism in human populations from in vitro data. Nat Rev Drug Discov 6:140-148.
30. Rowland A, Elliot DJ, Williams JA, Mackenzie PI, Dickinson RG, and Miners JO (2006) In vitro characterisation of lamotrigine N2-glucuronidation and the lamotrigine-valproic acid interaction. Drug Metab Dispos 34:1055-1062.
31. Rowland A, Gaganis P, Elliot DJ, Mackenzie PI, Knights KM, and Miners JO (2007) Binding of inhibitory fatty acids is responsible for the enhancement of UDP Glucuronosyltransferase 2B7 activity by albumin: implications for in vitro-in vivo extrapolation. J Pharmacol Exp Ther 321:137-147.
32. Soars MG, Burchell B, and Riley RJ (2002) In vitro analysis of human drug glucuronidation and prediction of in vivo metabolic clearance. J Pharmacol Exp Ther 301:382-390.
33. Svendsen TL, Kristensen MB, Hansen JM, and Skovsted L (1975) The influence of disulfiram on the half life and metabolic clearance rate of diphenylhydantoin and tolbutamide in man. Eur J Clin Pharmacol 9:439-441.
34. Tang C, Lin Y, Rodrigues AD, and Lin JH (2002) Effect of albumin on phenytoin and tolbutamide metabolism in human liver microsomes: an impact more than protein binding. Drug Metab Dispos 30:648-654.
35. Tassaneeyakul W, Veronese ME, Birkett DJ, Doecke CJ, McManus ME, Sansom LN, and Miners JO (1992) Co-regulation of phenytoin and tolbutamide metabolism in humans. Br J Clin Pharmacol 34:494-498.
36. Tsoutsikos P, Miners JO, Stapleton A, Thomas A, Sallustio BC, and Knights KM (2004) Evidence that unsaturated fatty acids are potent inhibitors of renal UDPglucuronosyltransferases (UGT): kinetic studies using human kidney cortical microsomes and recombinant UGT1A9 and UGT2B7. Biochem Pharmacol 67:191-199.
37. Uchaipichat V, Winner LK, Mackenzie PI, Elliot DJ, Williams JA, and Miners JO (2006) Quantitative prediction of in vivo inhibitory drug interactions involving glucuronidated drugs from in vitro data: the effect of fluconazole on zidovudine glucuronidation. Br J Clin Pharmacol 61:427-439.
38. Wang J-S, Wen X, Backman JT, and Neuvonen PJ (2002) Effect of albumin and cytosol on enzyme kinetics of tolbutamide hydroxylation and inhibition of CYP2C9 by gemfibrozil in human liver microsomes. J Pharmacol Exp Ther 302:43-49.
39. Waskell L, Koblin D, and Canova-Davis E (1982) The lipid composition of human liver microsomes. Lipids 17:317-320.
40. Zhou Q, Matsumoto S, Ding LR, Fischer NE, and Inaba T (2004) The comparative interaction of human and bovine serum albumins with CYP2C9 in human liver microsomes. Life Sci 75:2145-2155.